Vertex Pharmaceuticals Incorporated

🇺🇸NASDAQ Global Select
Back to all articles
Vertex Pharmaceuticals Incorporated stock analysis VRTX overview
Slightly Bullish +25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), Pfizer (PFE) and Guardant Health (GH)

📊 Analyst Chase Knickerbocker of Craig-Hallum maintained a Buy rating on Phathom Pharmaceuticals with an 88.0% upside from current levels.

💰 Phathom Pharmaceuticals has a Strong Buy consensus and a price target of $22.00, indicating significant potential growth.

🏥 Needham also assigned a Buy rating to Phathom on April 16 with a higher $28.00 price target.

⚠️ Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer with a $28.00 price target, reflecting cautious sentiment.

📉 Pfizer currently has a Moderate Buy consensus with an average price target of $29.16, representing only 5.9% upside.

🏭 Bernstein maintained a Hold rating on Pfizer in a report issued on April 21 with a $30.00 price target.

🧬 William Blair analyst Andrew Brackmann maintained a Buy rating on Guardant Health today following its market close at $83.93.

📈 Guardant Health has a Strong Buy consensus rating from the Street with an average price target of $131.41, implying 52.7% upside.

🏢 Mizuho Securities also maintained a Buy rating on Guardant Health in April with a $135.00 price target.

🔄 Craig-Hallum analyst Knickerbocker covers the Healthcare sector and boasts a 58.3% success rate and 35.1% average return.

🤝 Morgan Stanley analyst Flynn has a 56.2% success rate and focuses on stocks including Vertex Pharmaceuticals.

📊 William Blair analyst Brackmann is a 4-star analyst covering healthcare biotech companies like Adaptive Biotechnologies.

Bullish Signals
  • Phathom Pharmaceuticals received a Strong Buy analyst consensus with an impressive $22.00 price target, representing an 88.0% upside from current share levels.
  • Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Phathom and has a strong track record with a 5-star rating, a 35.1% average return, and a 58.3% success rate.
  • Needham also assigned a Buy rating to Phathom Pharmaceuticals with a $28.00 price target in a report issued on April 16.
  • Guardant Health holds a Strong Buy analyst consensus with a $131.41 average price target, implying a significant 52.7% upside potential from current levels.
  • William Blair analyst Andrew Brackmann maintained a Buy rating on Guardant Health, backed by a 4-star analyst rating and 12.5% average return.
  • Mizuho Securities supported the bullish sentiment with a Buy rating on Guardant Health at $135.00 in a report issued on April 13.
Risk Factors
  • The article is overwhelmingly positive for all three mentioned companies (Phathom, Pfizer, Guardant), with no specific negative risks or caveats explicitly detailed beyond the 'Conflicting Sentiments' header which primarily lists Buy/Hold ratings rather than sell recommendations.
  • While Terence Flynn of Morgan Stanley maintained a Hold rating on Pfizer, this is not inherently negative but indicates a lack of aggressive upside compared to Strong Buy consensus.
  • The analyst success rate for William Blair's Andrew Brackmann is listed as 47.7%, which is below the majority benchmark and may suggest potential inconsistency in his bullish Guardant Health recommendations.
Full Analysis
Analysts have issued conflicting ratings on three healthcare companies, with Phathom Pharmaceuticals (PHAT), Pfizer (PFE), and Guardant Health (GH) receiving mixed sentiment from the Street. Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Phathom Pharmaceuticals today, noting that shares closed at $11.28 last Tuesday. TipRanks reports Knickerbocker as a 5-star analyst with a 35.1% average return and a 58.3% success rate. The overall consensus for Phathom is Strong Buy, supported by a price target consensus of $22.00 which implies an 88.0% upside from current levels. In addition to the recent rating, Needham assigned a Buy rating with a $28.00 price target in a report dated April 16, while Barclays recently upgraded Phathom to Overweight from Equal Weight and Cantor expects management to meet with investors regarding its profitable path post-ramp-up. In contrast, Pfizer faces more cautious ratings from Wall Street analysts. Terence Flynn from Morgan Stanley maintained a Hold rating on the stock today, setting a price target of $28.00 against shares that closed at $26.77 last Tuesday. TipRanks profiles Flynn as a 5-star analyst with an average return of 9.4% and a 56.2% success rate covering various healthcare stocks including Structure Therapeutics and Arvinas. Despite individual Hold ratings, the current consensus for Pfizer remains Moderate Buy with an average price target of $29.16, representing a 5.9% upside. Bernstein previously maintained a Hold rating on April 21 with a $30.00 price target, indicating limited immediate growth expectations from some quarters. Guardant Health has received strong support from several analysts with recent ratings leaning bullish. William Blair analyst Andrew Brackmann maintained a Buy rating today, with shares closing at $83.93 last Tuesday. TipRanks lists Brackmann as a 4-star analyst with a 12.5% average return and a 47.7% success rate. General market sentiment for Guardant is Strong Buy, reflected in a price target consensus of $131.41 implying a 52.7% upside potential from current levels. Mizuho Securities previously maintained a Buy rating on April 13 with a higher $135.00 price target, further solidifying the positive outlook for Guardant Health relative to Pfizer and Phathom Pharmaceuticals in this sector review.